Universal Vision Biotechnology Co., Ltd. Statistics
Universal Vision Biotechnology Co., Ltd. (3218) Stock Statistics & Valuation Metrics
Total Valuation
Universal Vision Biotechnology Co., Ltd. has a market cap or net worth of TWD 10.72B. The enterprise value is TWD 12.14B.
- Market Cap
- TWD 10.72B
- Enterprise Value
- TWD 12.14B
Share Statistics
Universal Vision Biotechnology Co., Ltd. has 84,724,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 84,724,900
- Owned by Insiders
- ―
- Owned by Institutions
- 1.92%
Financial Efficiency
Universal Vision Biotechnology Co., Ltd.’s return on equity (ROE) is 0.26 and return on invested capital (ROIC) is 20.25%.
- Return on Equity (ROE)
- 0.26
- Return on Assets (ROA)
- 0.17
- Return on Invested Capital (ROIC)
- 20.25%
- Return on Capital Employed (ROCE)
- 0.27
- Revenue Per Employee
- 10.48M
- Profits Per Employee
- 2.60M
- Employee Count
- 401
- Asset Turnover
- 0.69
- Inventory Turnover
- 5.67
Valuation Ratios
The current PE Ratio of Universal Vision Biotechnology Co., Ltd. is 9.29. Universal Vision Biotechnology Co., Ltd.’s PEG ratio is 0.32.
- PE Ratio
- 9.29
- PS Ratio
- 2.49
- PB Ratio
- 2.74
- Price to FCF
- 8.14
- Price to Operating Cash Flow
- 5.98
- PEG Ratio
- 0.32
Income Statement
In the last 12 months, Universal Vision Biotechnology Co., Ltd. had revenue of 4.20B and earned 1.04B in profits. Earnings per share was 12.31.
- Revenue
- 4.20B
- Gross Profit
- 2.48B
- Operating Income
- 1.38B
- Pretax Income
- 1.35B
- Net Income
- 1.04B
- EBITDA
- 1.92B
- Earnings Per Share (EPS)
- 12.31
Cash Flow
In the last 12 months, operating cash flow was 1.78B and capital expenditures -470.58M, giving a free cash flow of 1.31B billion.
- Operating Cash Flow
- 1.78B
- Free Cash Flow
- 1.31B
- Free Cash Flow per Share
- 15.43
Dividends & Yields
Universal Vision Biotechnology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 6.13%
- Dividend Per Share
- ―
- Dividend Yield
- 6.13%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 12.39%
- Earnings Yield
- 10.83%
Stock Price Statistics
- Beta
- 0.41
- 52-Week Price Change
- -9.32%
- 50-Day Moving Average
- 133.22
- 200-Day Moving Average
- 133.54
- Relative Strength Index (RSI)
- 36.75
- Average Volume (3m)
- 184.60K
Important Dates
Universal Vision Biotechnology Co., Ltd. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Universal Vision Biotechnology Co., Ltd. as a current ratio of 2.92, with Debt / Equity ratio of 26.43%
- Current Ratio
- 2.92
- Quick Ratio
- 2.62
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.15
- Interest Coverage Ratio
- 55.55
Taxes
In the past 12 months, Universal Vision Biotechnology Co., Ltd. has paid 290.98M in taxes.
- Income Tax
- 290.98M
- Effective Tax Rate
- 0.22
Enterprise Valuation
Universal Vision Biotechnology Co., Ltd. EV to EBITDA ratio is 5.92, with an EV/FCF ratio of 8.46.
- EV to Sales
- 2.59
- EV to EBITDA
- 5.92
- EV to Free Cash Flow
- 8.46
- EV to Operating Cash Flow
- 6.22
Balance Sheet
Universal Vision Biotechnology Co., Ltd. has TWD 1.03B in cash and marketable securities with TWD 1.51B in debt, giving a net cash position of -TWD 478.92M billion.
- Cash & Marketable Securities
- TWD 1.03B
- Total Debt
- TWD 1.51B
- Net Cash
- -TWD 478.92M
- Net Cash Per Share
- -TWD 5.65
- Tangible Book Value Per Share
- TWD 46.00
Margins
Gross margin is 56.51%, with operating margin of 31.23%, and net profit margin of 26.73%.
- Gross Margin
- 56.51%
- Operating Margin
- 31.23%
- Pretax Margin
- 33.15%
- Net Profit Margin
- 26.73%
- EBITDA Margin
- 43.66%
- EBIT Margin
- 33.68%
Analyst Forecast
The average price target for Universal Vision Biotechnology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 0.24%
- EPS Growth Forecast
- 28.93%
